Alpha CrossLaps® (CTX-I) EIA
Disease Areas: Bone metabolism
Format: EIA
Description
The Alpha CrossLaps® ELISA is an enzyme-linked immunosorbent assay for the quantifi cation of nonisomerized fragments of C-terminal telopeptides of Type-I collagen (α CTX-I) in human urine.
The Alpha CrossLaps® ELISA is intended for use as an indicator of degradation of non-isomerized bone collagen and may be used as an aid in the identification of skeletal metastases in patients with breast and prostate cancer. In addition, the Alpha CrossLaps® ELISA may be applied to humans as an aid in the diagnosis of Paget’s disease and the monitoring of anti-resorptive therapy in patients with Paget’s disease
Physiology
- Type I collagen accounts formore than 90%of the organic matrix of bone and is synthesised primarily in bone. During renewal of the skeleton, Type I collagen is degraded, and small peptide fragments are excreted into the urine. These fragments can bemeasured by the Alpha CrossLaps® ELISA. Themeasurements of the specific degradation products of Type I collagen (Alpha CrossLaps®) in human urine have been reported as useful assessment of bone resorption in Paget’s disease and for detection of bonemetastases in prostate and east cancer.
Assay Details
| Format | 96 Wells |
| Code | AC-04F1 |
| Methodology | EIA |
| Calibrators | 6 |
| Controls | 2 |
| Assay Range | 0.1-10.0 ng/mL |
| Specimen Type | Urine |
| Sensitivity | 0.8 ng/mL |
| Specimen Volume | 25 µL |
| Incubation time | 60 + 15 min. at 2-8oC |
Product information correct as of 6th March 2012